ArticleCancer immunology research2023

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Apostolia M Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.